fbpx
QQQ
+ 2.17
342.19
+ 0.63%
DIA
+ 0.40
338.38
+ 0.12%
SPY
+ 1.53
419.33
+ 0.36%
TLT
-0.02
143.31
-0.01%
GLD
-0.45
167.40
-0.27%

MindMed To Include MDMA to Research Portfolio

May 27, 2020 7:36 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
MindMed To Include MDMA to Research Portfolio

Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. (NEO: MMED) (OTCQB:MMEDF) announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline.

The move comes as part of the company’s exclusive collaboration agreement with the University Hospital Basel’s Liechti Lab

A Potential in Combining MDMA with Other Psychedelics

“We see an amazing opportunity to optimize the subjective effect profiles of known psychedelics like LSD and MDMA to potentially make a more advanced and comfortable therapeutic experience for the patient,” JR Rahn, CEO of MindMed, told Benzinga.

University of Basel Professor Dr. Matthias Liechti, who was one of the original scientific researchers to discover the mechanism of action of MDMA in the 1990s, said that his lab has generated a large amount of data on the pharmacokinetics, pharmacogenetics and safety of MDMA in over 10 years of clinical research.

MindMed will leverage Liechti’s experience in leading multiple clinical trials of the safety profile of MDMA to explore ways to develop psychedelic therapies combining MDMA and LSD.

“We are most interested in how MDMA can be combined with other medicines or psychedelics and plan to focus our R+D funding on developing this concept further for patients,” said Rahn.

MDMA was granted “Breakthrough Therapy” designation by the FDA in 2017, revealing the agency’s consideration that MDMA-assisted psychotherapy may have a meaningful advantage over available medications for PTSD.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. read more

Psychedelics Company Atai Life Sciences Files For Nasdaq Listing In Sector's Highly Anticipated IPO

Atai Life Sciences could soon become the second psychedelics company to list on a major U.S. exchange. The Berlin-based biotech firm filed Tuesday with the SEC to raise $100 million in an IPO using the ticker symbol "ATAI." read more

Could Psychedelic Medicines Have Helped Prevent DMX's Overdose?

It’s sad to say, but it seems like the only time we pay attention to the addiction problem in this country is when someone famous overdoses. Such is the case with DMX, who I would argue is one of the most unique and gifted rappers ever. read more

Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree

MindMed Posts 2020 Financials, New MDMA Dosing Study and 18-MC Patent Application MindMed (OTCQB:MMEDF) released its full-year 2020 financial results.  read more